PF 04937319
PF 04937319 structure
|
Common Name | PF 04937319 | ||
|---|---|---|---|---|
| CAS Number | 1245603-92-2 | Molecular Weight | 432.432 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C22H20N6O4 | Melting Point | N/A | |
| MSDS | USA | Flash Point | N/A | |
Use of PF 04937319PF-04937319 is a glucokinase activator (GKA) with EC50 value of 154.4 μM, one of the most promising strategies for the treatment of type 2 diabetes mellitus[1].PF-04937319 is designed to maintain glucose-lowering efficacy while mitigating the risk of hypoglycaemia observed with many other GKAs[2]. |
| Name | 7E99B9ZM19 |
|---|---|
| Synonym | More Synonyms |
| Description | PF-04937319 is a glucokinase activator (GKA) with EC50 value of 154.4 μM, one of the most promising strategies for the treatment of type 2 diabetes mellitus[1].PF-04937319 is designed to maintain glucose-lowering efficacy while mitigating the risk of hypoglycaemia observed with many other GKAs[2]. |
|---|---|
| Related Catalog | |
| Target |
EC50: 154.4 μM (GSA) (PF-04937319)[1] |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Molecular Formula | C22H20N6O4 |
| Molecular Weight | 432.432 |
| Exact Mass | 432.154602 |
| LogP | 1.29 |
| Index of Refraction | 1.667 |
| RIDADR | NONH for all modes of transport |
|---|
|
Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes.
Diabetes Obes. Metab. 17(8) , 751-9, (2015) To assess the efficacy and safety of a range of doses of a systemic, partial, glucokinase activator, PF-04937319, as add-on therapy to metformin, in patients with type 2 diabetes mellitus (T2DM).Patie... |
|
|
Metabolites in safety testing assessment in early clinical development: a case study with a glucokinase activator.
Drug Metab. Dispos. 42(11) , 1926-39, (2014) The present article summarizes Metabolites in Safety Testing (MIST) studies on a glucokinase activator, N,N-dimethyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yl)oxy)pyrimidine-2-ca... |
|
|
The relationship of glucokinase activator-induced hypoglycemia with arteriopathy, neuronal necrosis, and peripheral neuropathy in nonclinical studies.
Toxicol. Pathol. 42(4) , 696-708, (2014) Glucokinase activators (GKAs) are being developed for the treatment of type 2 diabetes. The toxicity of 4 GKAs (PF-04279405, PF-04651887, piragliatin, and PF-04937319) was assessed in mice, rats, dogs... |
| 2-Pyrimidinecarboxamide, N,N-dimethyl-5-[[2-methyl-6-[[(5-methyl-2-pyrazinyl)amino]carbonyl]-4-benzofuranyl]oxy]- |
| N,N-Dimethyl-5-({2-Methyl-6-[(5-Methylpyrazin-2-Yl)carbamoyl]-1-Benzofuran-4-Yl}oxy)pyrimidine-2-Carboxamide |
| 7E99B9ZM19 |
| N,N-Dimethyl-5-({2-methyl-6-[(5-methyl-2-pyrazinyl)carbamoyl]-1-benzofuran-4-yl}oxy)-2-pyrimidinecarboxamide |
| PF-04937319 |